Stereotaxis (STXS) Q2 2026 Earnings Call Transcript

Stereotaxis (STXS) reported Q2 2026 revenue of $7.7M, down from $8.8M YoY due to no robotic system delivery. Robotic catheter revenue grew 270% sequentially to $1M. Recurring revenue increased to $6.2M. Gross margin was 58%. The company expects cash flow profitability by H1 2027 and guided Q3/Q4 recurring revenue at $7M and $8M, respectively. Management highlighted supply constraints and transition risks.

Original reporting
Published Aug 18, 2026, 11:15 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 18, 2026, 11:39 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Stereotaxis (STXS) Q2 2026 Earnings Call Transcript — source image
Decision brief

The 30-second read

$STXSNeutralMed
01

Why it matters

The call centers on Q2 results and forward guidance, with management emphasizing supply constraints limiting robotic system deliveries and backlog conversion, while recurring revenue grows on MAGiC adoption. It also reiterates a profitability timeline (cash-flow profitability in 1H 2027) tied to catheter ramp and manufacturing output increases.

02

Market read

Traders will likely focus on whether the company can convert backlog into deliveries given stated manufacturing bottlenecks, and whether guided recurring revenue and systems installation plans are achievable into 3Q and 4Q 2026.

03

What to watch

The guidance depends on installations (GenesisX, Synchrony) and hospital standardization decisions, which could slip if compatibility efforts with X-ray manufacturers take longer than expected.

Relevance 8/10Novelty 7/10Timing: post-market, after-hours earnings call transcript (Aug. 18)

Background

Stereotaxis is transitioning from a legacy model toward a proprietary robotic ecosystem (MAGiC catheter, GenesisX robot, Synchrony digital surgery system) and recently closed the Robocath acquisition (July 2026).

Company-level read

Ticker impact

$STXSNeutralMedium confidence
Context

Stereotaxis reported Q2 2026 revenue of $7.7M, guided recurring revenue to $7M in Q3 and $8M in Q4, and flagged supply constraints from contract manufacturer Osypka.

Expected impact

Moderate upside bias if investors believe Osypka output can expand fast enough to sustain the guided recurring revenue and systems installation cadence; downside risk if supply remains the binding constraint.

Evidence & confidence

The call provides multiple forward-looking datapoints (recurring and systems guidance, cash-flow profitability timing, and explicit supply-constrained backlog) that can reprice expectations, but it is still an earnings-call transcript rather than a fresh filing or surprise datapoint.

Market effects

Highlights a medtech commercialization model shift toward proprietary consumables and recurring revenue, with manufacturing capacity as the key gating factor.

Primarily US adoption narrative (12 MAGiC sites, GenesisX purchase by an academic medical center), which can influence US medtech sentiment.

Mentions global patient treatment volume (>150,000) but the actionable near-term catalysts are US supply and installation schedules.

Counterpoint

Even with improving adoption, the systems revenue decline and negative free cash flow suggest the business may remain dependent on continued manufacturing scale-up before profitability becomes credible.

Key entities

  • Stereotaxis, Inc.

    Reported Q2 2026 financials and provided Q3/Q4 recurring and systems revenue guidance, while citing supply constraints from contract manufacturing.

  • Osypka

    Contract manufacturer cited as the source of supply constraints limiting catheter/robotic system output.

  • Robocath

    Endovascular robotics company acquired by Stereotaxis in July 2026 to expand into multi-specialty navigation.

  • MAGiC

    Proprietary robotic catheter launched in the US, driving recurring catheter revenue growth and adoption at 12 US sites.

  • GenesisX

    Robotic magnetic navigation system; management expects installations and compatibility steps to broaden adoption.

Related articles

$STXSHigh

Why is Stereotaxis stock sliding today?

Stereotaxis (STXS) fell 14.6% after Q3 2026 results missed estimates, with a $0.07 adjusted loss per share and $8.9M revenue. Supply shortages of MAGiC catheters and a $24M convertible note financing at $1.21/share raised concerns. TD Cowen cut its price target to $2.00. The stock hit a 52-week low of $0.80.

$STXSMedAI 8/10

20 robotic heart procedures had no device-related adverse events.

Stereotaxis (NYSE: STXS) announced 100% clinical success and no device-related adverse events in 20 first-in-human robotic heart procedures using Robocath's next-generation system. The study, presented at TCT 2026, showed 95% technical success and no physician radiation exposure. Robocath is a subsidiary of Stereotaxis, focusing on advanced robotic innovations for interventional cardiology.

$STXSMed

Stereotaxis Reports 2026 Second Quarter Financial Results & Business Updates

Stereotaxis, Inc. (STXS) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Stereotaxis Reports 2026 Second Quarter Financial Results & Business Updates ● Robotic catheter revenue surpasses $1M in the quarter, growing 270% sequentially ● First GenesisX robotic system purchase by US hospital to be installed this fall ● Multiple Synchrony digi

$NIUMed

Niu Tech (NIU) Q3 2026 Earnings Call Transcript

Niu Tech (NIU) reported Q3 2026 earnings, with total sales volume up 15.4% YoY to 534,057 units. Revenue was RMB 1.71 billion, up 1.2% YoY. China sales grew 8.6% YoY, while international sales surged 226%. Gross margin expanded to 18.0%. The company highlighted strong growth in electric motorcycles, which accounted for 56% of China sales, and strategic product launches.